GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Spermosens AB (XSAT:SPERM) » Definitions » Beta

Spermosens AB (XSAT:SPERM) Beta : -0.44 (As of Apr. 02, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Spermosens AB Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2025-04-02), Spermosens AB's Beta is -0.44.


Spermosens AB Beta Historical Data

The historical data trend for Spermosens AB's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spermosens AB Beta Chart

Spermosens AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beta
Get a 7-Day Free Trial - - - - 0.40

Spermosens AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 1.01 0.96 0.40

Competitive Comparison of Spermosens AB's Beta

For the Diagnostics & Research subindustry, Spermosens AB's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spermosens AB's Beta Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Spermosens AB's Beta distribution charts can be found below:

* The bar in red indicates where Spermosens AB's Beta falls into.


;
;

Spermosens AB Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Spermosens AB  (XSAT:SPERM) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Spermosens AB Beta Related Terms

Thank you for viewing the detailed overview of Spermosens AB's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Spermosens AB Business Description

Traded in Other Exchanges
Address
Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Spermosens AB is developing a revolutionary platform technology for diagnosing male-factor infertility and directing to the right infertility treatment. It is a developer of medical device products for male infertility, individualizing In Vitro Fertilization (IVF) diagnostics and treatment creating a new standard for faster and safer IVF treatments.

Spermosens AB Headlines

No Headlines